Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium (177Lu) oxodotreotide vs high-dose long-acting octreotide in advanced GEP-NETs
CTR20230775Phase 3Active
- Sponsor
- Hengrui Pharma
- Start
- Jul 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate in Gastroenteropancreatic Carcinoid Tumor, sponsored by Hengrui Pharma. Started Jul 2023; status: active.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on CTR20230775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230775.